The Potential of panHER Inhibition in Cancer

Frontiers in Oncology

Volumn 5, Issue , 2015, Pages

  Wang, Xiaochun ^a   Batty, Kathleen M ^a   Crowe, Philip J ^a   Goldstein, David ^a   Yang, Jia Lin ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

drug resistance; EGFR; HER signaling pathways; panHER inhibitors; targeted therapy

Indexed keywords

EID: 85046642813     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00002     Document Type: Review

References (123)

1. Begg S Vos T Barker B Stevenson C Stanley L Lopez AD. The Burden of Disease and Injury in Australia 2003. Australian Institute of Health and Welfare (2007). Available from: http://www.aihw.gov.au/publication-detail/?id=6442467990
2. Normanno N Maiello MR De Luca A. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action? J Cell Physiol (2003) 194(1):13–9.10.1002/jcp.1019412447985
3. Ogino A Kitao H Hirano S Uchida A Ishiai M Kozuki T et al. Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line. Cancer Res (2007) 67(16):7807–14.10.1158/0008-5472.CAN-07-068117699786
4. Kong A Calleja V Leboucher P Harris A Parker PJ Larijani B. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells. PLoS One (2008) 3(8):e2881.10.1371/journal.pone.000288118682844
5. Wang X Crowe PJ Goldstein D Yang J-L. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int J Oncol (2012) 41(4):1181–91.10.3892/ijo.2012.156822842992
6. Engelman JA Zejnullahu K Mitsudomi T Song Y Hyland C Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 316(5827):1039–43.10.2307/2003628817463250
7. Bean J Brennan C Shih J-Y Riely G Viale A Wang L et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 104(52):20932–7.10.1073/pnas.071037010418093943
8. Zaczek A Brandt B Bielawski KP. The diverse signaling network of EGFR, HER2, HER3 and HER4 tyrosine kinase receptors and the consequences for therapeutic approaches. Histol Histopathol (2005) 20(3):1005–15.15944951
9. Yarden Y Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol (2001) 2(2):127–37.10.1038/3505207311252954
10. Citri A Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol (2006) 7(7):505–16.10.1038/nrm196216829981
11. Rawlings JS Rosler KM Harrison DA. The JAK/STAT signaling pathway. Cell Sci Glance (2004) 117(8):1281–3.10.1242/jcs.00963
12. Oliviera-Cunha M Newman WG Siriwardena AK. Epidermal growth factor receptor in pancreatic cancer. Cancers (Basel) (2011) 3(2):1513–26.10.3390/cancers302151324212772
13. Yano S Kondo K Yamaguchi M Richmond G Hutchison M Wakeling A et al. Distribution and function of EGFR in human tissue and the effect of EGFR tyrosine kinase inhibition. Anticancer Res (2003) 23(5A):3639–50.14666659
14. Zahorowska B Crowe PJ Yang JL. Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J Cancer Res Clin Oncol (2009) 135(9):1137–48.10.1007/s00432-009-0622-419533170
15. Mor A Philips MR. Compartmentalized Ras/MAPK signaling. Annu Rev Immunol (2006) 24:771–800.10.1146/annurev.immunol.24.021605.09072316551266
16. Nahta R. New developments in the treatment of HER2-positive breast cancer. Breast Cancer Targets Ther (2012) 4:53–64.10.2147/BCTT.S24976
17. Nahta R Yuan LX Zhang B Kobayashi R Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res (2005) 65(23):11118–28.10.1158/0008-5472.CAN-04-384116322262
18. Nahta R Yu D Hung MC Hortobagyi GN Esteva FJ. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol (2006) 3(5):269–80.10.1038/ncponc050916683005
19. Nahta R Esteva FJ. Trastuzumab: triumphs and tribulations. Oncogene (2007) 26(25):3637–43.10.1038/sj.onc.121037917530017
20. Browne BC Crown J Venkatesan N Duffy MJ Clynes M Slamon D et al. Inhibition of IGF1R activity enhances response to trastuzumab in HER-2-positive breast cancer cells. Ann Oncol (2011) 22(1):68–73.10.1093/annonc/mdq34920647220
21. Rubin I Yarden Y. The basic biology of HER2. Ann Oncol (2001) 12(Suppl 1):S3–8.10.1023/A:1013026527758
22. Liu J Kern JA. Neuregulin-1 activates the JAK-STAT pathway and regulates lung epithelial cell proliferation. Am J Respir Cell Mol Biol (2002) 27(3):306–13.10.1165/rcmb.485012204892
23. Tanner M Jarvinen P Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res (2001) 61(14):5345–8.11454672
24. Hudis CA. Trastuzumab – mechanism of action and use in clinical practice. N Engl J Med (2007) 357(1):39–51.10.1056/NEJMra043186
25. Shou J Massarweh S Osborne CK Wakeling AE Ali S Weiss H et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst (2004) 96(12):926–35.10.1093/jnci/djh16615199112
26. Hynes NE MacDonald G. ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol (2009) 21(2):177–84.10.1016/j.ceb.2008.12.01019208461
27. Way TD Lin JK. Role of HER2/HER3 co-receptor in breast carcinogenesis. Future Oncol (2005) 1(6):841–9.10.2217/14796694.1.6.84116556064
28. Hsieh AC Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer (2007) 97(4):453–7.10.1038/sj.bjc.660391017667926
29. Fresno Vara JA Casado E de Castro J Cejas P Belda-Iniesta C Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev (2004) 30(2):193–204.10.1016/j.ctrv.2003.07.007
30. Campbell MR Amin D Moasser MM. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res (2010) 16(5):1373–83.10.1158/1078-0432.CCR-09-121820179223
31. Tanner B Hasenclever D Stern K Schormann W Bezler M Hermes M et al. ErbB-3 predicts survival in ovarian cancer. J Clin Oncol (2006) 24(26):4317–23.10.1200/JCO.2005.04.839716896008
32. Karamouzis MV Badra FA Papavassiliou AG. Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol (2007) 39(5):851–6.10.1016/j.biocel.2006.11.01717254832
33. Gilbertson RJ Perry RH Kelly PJ Pearson AD Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. Cancer Res (1997) 57(15):3272–80.9242460
34. Olayioye MA Neve RM Lane HA Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J (2000) 19(13):3159–67.10.1093/emboj/19.13.3159
35. Zhang K Sun J Liu N Wen D Chang D Thomason A et al. Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J Biol Chem (1996) 271(7):3884–90.10.1074/jbc.271.7.38848632008
36. Holbro T Hynes NE. ErbB receptors: directing key signaling networks throughout life. Annu Rev Pharmacol Toxicol (2004) 44:195–217.10.1146/annurev.pharmtox.44.101802.12144014744244
37. Roskoski R Jr. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res (2014) 79:34–74.10.1016/j.phrs.2013.11.00224269963
38. Shor AC Agresta SV D’Amato GZ Sondak VK. Therapeutic potential of directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control (2008) 15(1):47–54.18094660
39. Arora A Scholar EM. Role of tyrosine kinase inhibitors in cancer therapy. J Pharmacol Exp Ther (2005) 315(3):971–9.10.1124/jpet.105.08414516002463
40. Valabrega G Montemurro F Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol (2007) 18(6):977–84.10.1093/annonc/mdl47517229773
41. Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology (2006) 20(5 Suppl 2):5–13.16736978
42. Kosaka T Yamaki E Mogi A Kuwano H. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol (2011) 2011:165214.10.1155/2011/16521421687596
43. Yun CH Mengwasser KE Toms AV Woo MS Greulich H Wong KK et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A (2008) 105(6):2070–5.10.1073/pnas.070966210518227510
44. Nguyen KS Kobayashi S Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer (2009) 10(4):281–9.10.3816/CLC.2009.n.03919632948
45. Cross D Ashton S Nebhan C Eberlein C Finlay MRV Hughes G et al. eds. AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm+) and resistance (T790M) mutations in advanced lung adenocarcinoma. Mol Cancer Ther (2013) 12(11 Suppl):A109.10.1158/1535-7163.TARG-13-A109
46. Ballard P Ashton S Cross D Dimelow R Yates J, eds. Integrating the pre-clinical pharmacokinetic, pharmacodynamics, and efficacy data for AZD9291, an oral, irreversible inhibitor of EGFR activating (EGFRm+) and resistant (EGFRm+/T790M) mutations and an active metabolite to predict the human pharmacokinetics and potential efficacious dose in patients. Mol Cancer Ther (2013) 12(11 Suppl):B212.
47. Finlay MRV Anderson M Ashton S Ballard PG Bradbury RH Butterworth S et al. eds. Discovery of and first disclosure of the clinical candidate AZD9291, a potent and selective third-generation EGFR inhibitor of both activating and T790M resistant mutations that spares the wild type form of the receptor. Mol Cancer Ther (2013) 12(11 Suppl):B94.
48. Carmi C Mor M Petronini PG Alfieri RR. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Biochem Pharmacol (2012) 84(11):1388–99.10.1016/j.bcp.2012.07.03122885287
49. Soria J-C Sequist LV Gadgeel S Goldman J Wakelee H Varga A et al. eds. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M). J Thorac Oncol (2013) 8(2 Suppl):S141.
50. Ranson M Pao W Kim D-W Kim S-W Ohe Y Felip E et al. eds. AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFRm+) and resistance (T790M) mutations in advanced NSCLC. J Thorac Oncol (2013) 8(2 Suppl):S389.
51. Boccaccio C Ando M Tamagnone L Bardelli A Michieli P Battistini C et al. Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. Nature (1998) 391(6664):285–8.10.1038/346579440692
52. Puri N Salgia R. Synergism of EGFR and c-Met pathways, cross-talk and inhibition, in non-small cell lung cancer. J Carcinog (2008) 7:9.10.4103/1477-3163.4437219240370
53. Zucali PA Ruiz MG Giovannetti E Destro A Varella-Garcia M Floor K et al. Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. Ann Oncol (2008) 19(9):1605–12.10.1093/annonc/mdn24018467317
54. Scagliotti GV Novello S von Pawel J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat Rev (2013) 39(7):793–801.10.1016/j.ctrv.2013.02.00123453860
55. Robinson KW Sandler AB. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents. Oncologist (2013) 18(2):115–22.10.1634/theoncologist.2012-026223345546
56. Sanabria-Figueroa E Donnelly S Foy K Buss M Castellino RC Paplomata E et al. Insulin-like growth factor-1 receptor signaling increases the invasive potential of Human Epidermal Growth Factor Receptor 2-overexpressing breast cancer cells via Src-Focal Adhesion Kinase and Foxhead Box Protein M1. Mol Pharmacol (2015) 87(2):150–61.10.1124/mol.114.09538025391374
57. Lu Y Zi X Zhao Y Mascarenhas D Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst (2001) 93(24):1852–7.10.1093/jnci/93.24.185211752009
58. Karapetis CS Khambata-Ford S Jonker DJ O’Callaghan CJ Tu D Tebbutt NC et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med (2008) 359(17):1757–65.10.1056/NEJMoa080438518946061
59. Ciardello F Normanno N. HER2 signaling and resistance to the anti-EGFR monoclonal antibody cetuximab: a furthermore step toward personalised medicine for patients with colorectal cancer. Cancer Discov (2011) 1(6):472–4.10.1158/2159-8290.CD-11-026122586650
60. Corvinus FM Orth C Moriggl R Tsareva SA Wagner S Pfitzner EB et al. Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia (2005) 7(6):545–55.10.1593/neo.0457116036105
61. Béguelin W Flaqué MCD Proietti CJ Cayrol F Rivas MA Tkach M et al. Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 Function as a coactivator of Stat3. Mol Cell Biol (2010) 30(23):5456–72.10.1128/MCB.00012-1020876300
62. Wong TW Lee FY Yu C Luo FR Oppenheimer S Zhang H et al. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res (2006) 12(20):6186–93.10.1158/1078-0432.CCR-06-064217062696
63. Engelman JA Zejnullahu K Gale C-M Lifshits E Gonzales AJ Shimamura T et al. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 67(24):11924–32.10.1158/0008-5472.can-07-188518089823
64. Liu L Greger J Shi H Liu Y Greshock J Annan R et al. Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL. Cancer Res (2009) 69(17):6871–8.10.1158/0008-5472.CAN-08-449019671800
65. Soria JC Cortes J Massard C Armand JP De Andreis D Ropert S et al. Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors. Ann Oncol (2012) 23(2):463–71.10.1093/annonc/mdr13721576284
66. Kim T Lee K-W Oh D-Y. A phase I study of HM781-36B, a novel pan-HER inhibitor, in patients (pts) with advanced solid tumors. J Clin Oncol (2012) 30:3076.
67. Campos S Hamid O Seiden MV Oza A Plante M Potkul RK et al. Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer. J Clin Oncol (2005) 23(24):5597–604.10.1200/jco.2005.08.09116110019
68. Wong K-K. HKI-272 in non-small cell lung cancer. Clin Cancer Res (2007) 13(15):4593s–6s.10.1158/1078-0432.ccr-07-036917671147
69. Ramalingam SS Blackhall F Krzakowski M Barrios CH Park K Bover I et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2012) 30(27):3337–44.10.1200/jco.2011.40.943322753918
70. Janne PA Reckamp K Koczywas M Engelman JA Camidge DR Rajan A et al. eds. Efficacy and safety of PF-00299804 (PF299) in patients (pt) with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): a two-arm, phase II trial. J Clin Oncol (2009) 27(15 Suppl):8063.
71. Park K Heo DS Cho B Kim D Ahn M Lee S et al. eds. PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): a phase (P) I/II study. J Clin Oncol (2010) 28(15 Suppl):7599.
72. Mok T Spigel DR Park K Socinski MA Tung SY Kim D et al. eds. Efficacy and safety of PF-299804 (PF299), an oral, irreversible, pan-human epidermal growth factor receptor (pan-HER) tyrosine kinase inhibitor (TKI), as first-line treatment (tx) of selected patients (pts) with advanced (adv) non-small cell lung cancer (NSCLC). J Clin Oncol (2010) 28(15 Suppl):7537.
73. Jänne PA Boss DS Camidge DR Britten CD Engelman JA Garon EB et al. Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res (2011) 17(5):1131–9.10.1158/1078-0432.ccr-10-122021220471
74. Takahashi T Boku N Murakami H Naito T Tsuya A Nakamura Y et al. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors. Invest New Drugs (2012) 30(6):2352–63.10.1007/s10637-011-9789-z
75. Abdul Razak AR Soulières D Laurie SA Hotte SJ Singh S Winquist E et al. A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck. Ann Oncol (2013) 24(3):761–9.10.1093/annonc/mds50323108949
76. Eskens FALM Mom CH Planting AST Gietema JA Amelsberg A Huisman H et al. A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours. Br J Cancer (2008) 98(1):80–5.10.1038/sj.bjc.660410818026190
77. Yap TA Vidal L Adam J Stephens P Spicer J Shaw H et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol (2010) 28(25):3965–72.10.1200/jco.2009.26.727820679611
78. Murakami H Tamura T Takahashi T Nokihara H Naito T Nakamura Y et al. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4). Cancer Chemother Pharmacol (2012) 69(4):891–9.10.1007/s00280-011-1738-122071596
79. Gordon M Mendelson D Gross M Uttenreuther-Fischer M Ould-Kaci M Zhao Y et al. A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors. Invest New Drugs (2013) 31(2):409–16.10.1007/s10637-012-9904-9
80. Vermorken JB Rottey S Ehrnrooth E Pelling K Lahogue A Wind S et al. A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors. Ann Oncol (2013) 24(5):1392–400.10.1093/annonc/mds63323293114
81. Awada AH Dumez H Hendlisz A Wolter P Besse-Hammer T Uttenreuther-Fischer M et al. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors. Invest New Drugs (2013) 31(3):734–41.10.1007/s10637-012-9880-023161334
82. Yang JC-H Shih J-Y Su W-C Hsia T-C Tsai C-M Ou S-HI et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol (2012) 13(5):539–48.10.1016/S1470-2045(12)70086-422452895
83. De Grève J Teugels E Geers C Decoster L Galdermans D De Mey J et al. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu. Lung Cancer (2012) 76(1):123–7.10.1016/j.lungcan.2012.01.00822325357
84. Schuler M Awada A Harter P Canon J Possinger K Schmidt M et al. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer. Breast Cancer Res Treat (2012) 134(3):1149–59.10.1007/s10549-012-2126-122763464
85. Miller VA Hirsh V Cadranel J Chen Y-M Park K Kim S-W et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol (2012) 13(5):528–38.10.1016/S1470-2045(12)70087-622452896
86. Yang JC-H Schuler MH Yamamoto N O’Byrne KJ Hirsh V Mok T et al. LUX-Lung 3: a randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. J Clin Oncol (2012) 30(18_suppl):LBA7500.
87. Wu YL Zhou C Hu C-P Feng JF Lu S Huang Y et al. LUX-Lung 6: a randomized, open-label, phase III study of afatinib (A) versus gemcitabine/cisplatin (GC) as first-line treatment for Asian patients (pts) with EGFR mutation-positive (EGFR M1) advanced adenocarcinoma of the lung. J Clin Oncol (2013) 31(15S):8016.
88. Ercan D Zejnullahu K Yonesaka K Xiao Y Capelletti M Rogers A et al. Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene (2010) 29(16):2346–56.10.1038/onc.2009.52620118985
89. Nam H-J Ching KA Kan J Kim H-P Han S-W Im S-A et al. Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer. Mol Cancer Ther (2012) 11(2):439–51.10.1158/1535-7163.mct-11-049422135232
90. Nam H-J Kim H-P Yoon Y-K Song S-H Min A-R Han S-W et al. The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines. Invest New Drugs (2012) 30(6):2148–60.10.1007/s10637-011-9782-622197904
91. Kalous O Conklin D Desai AJ O’Brien NA Ginther C Anderson L et al. Dacomitinib (PF-00299804), an irreversible pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib. Mol Cancer Ther (2012) 11(9):1978–87.10.1158/1535-7163.mct-11-073022761403
92. Ather F Hamidi H Fejzo MS Letrent S Finn RS Kabbinavar F et al. Dacomitinib, an irreversible pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. PLoS One (2013) 8(2):e56112.10.1371/journal.pone.005611223405260
93. Gonzales AJ Hook KE Althaus IW Ellis PA Trachet E Delaney AM et al. Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther (2008) 7(7):1880–9.10.1158/1535-7163.mct-07-223218606718
94. Kim SM Kwon O-J Hong YK Kim JH Solca F Ha S-J et al. Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation. Mol Cancer Ther (2012) 11(10):2254–64.10.1158/1535-7163.mct-12-031122891040
95. Boyer MJ Blackhall FH Park K Barrios CH Krzakowski MJ Taylor I et al. Efficacy and safety of PF299804 versus erlotinib (E): a global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after failure of chemotherapy (CT). J Clin Oncol (2010) 28(18 Suppl):LBA7523.
96. Press MF Cordon-Cardo C Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene (1990) 5(7):953–62.1973830
97. Scotlandi K Manara MC Hattinger CM Benini S Perdichizzi S Pasello M et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma. Eur J Cancer (2005) 41(9):1349–61.10.1016/j.ejca.2005.03.01515913990
98. Solca F Dahl G Zoephel A Bader G Sanderson M Klein C et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther (2012) 343(2):342–50.10.1124/jpet.112.19775622888144
99. Li D Ambrogio L Shimamura T Kubo S Takahashi M Chirieac LR et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene (2008) 27(34):4702–11.10.1038/onc.2008.10918408761
100. Bean J Riely GJ Balak M Marks JL Ladanyi M Miller VA et al. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res (2008) 14(22):7519–25.10.1158/1078-0432.ccr-08-015119010870
101. Perera SA Li D Shimamura T Raso MG Ji H Chen L et al. HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proc Natl Acad Sci U S A (2009) 106(2):474–9.10.1073/pnas.080893010619122144
102. Ioannou N Dalgleish AG Seddon AM Mackintosh D Guertler U Solca F et al. Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells. Br J Cancer (2011) 105(10):1554–62.10.1038/bjc.2011.39621970876
103. Stopfer P Marzin K Narjes H Gansser D Shahidi M Uttereuther-Fischer M et al. Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers. Cancer Chemother Pharmacol (2012) 69(4):1051–61.10.1007/s00280-011-1803-922200729
104. Afatinib US. Food and Drug Administration. (2013). Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm360574.htm
105. Huang Z Brdlik C Jin P Shepard HM. A pan-HER approach for cancer therapy: background, current status and future development. Expert Opin Biol Ther (2009) 9(1):97–110.10.1517/1471259080263042719063696
106. Torres MA Raju U Molkentine D Riesterer O Milas L Ang KK. AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs (2011) 29(4):554–61.10.1007/s10637-010-9389-320119866
107. Takezawa K Okamoto I Tanizaki J Kuwata K Yamaguchi H Fukuoka M et al. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther (2010) 9(6):1647–56.10.1158/1535-7163.mct-09-100920530710
108. Gieseg MA de Bock C Ferguson LR Denny WA. Evidence for epidermal growth factor receptor-enhanced chemosensitivity in combinations of cisplatin and the new irreversible tyrosine kinase inhibitor CI-1033. Anticancer Drugs (2001) 12(8):683–90.10.1097/00001813-200109000-0000711604556
109. Garland LL Hidalgo M Mendelson DS Ryan DP Arun BK Lovalvo JL et al. A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res (2006) 12(14 Pt 1):4274–82.10.1158/1078-0432.CCR-05-250716857802
110. Chiappori AA Ellis PM Hamm JT Bitran JD Eiseman I Lovalvo J et al. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer. J Thorac Oncol (2006) 1(9):1010–9.10.1097/01243894-200611000-0001517409987
111. Storniolo AM Pegram MD Overmoyer B Silverman P Peacock NW Jones SF et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol (2008) 26(20):3317–23.10.1200/JCO.2007.13.520218490651
112. McDonagh CF Huhalov A Harms BD Adams S Paragas V Oyama S et al. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3. Mol Cancer Ther (2012) 11(3):582–93.10.1158/1535-7163.mct-11-082022248472
113. Zhang B Lahdenranta J Du J Kirouac D Nguyen S Overland R et al. eds. MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclincal models of gastric cancer. Cancer Res (2013) 73(8 Suppl):4633.10.1158/1538-7445.AM2013-4633
114. Lahdenranta J Paragas V Kudla AJ Overland R Moyo VM Nielsen UB et al. eds. Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB-2-positive gastric and gastrophageal junction cancer. J Clin Oncol (2013) 31(4 Suppl):48.
115. Kirouac DC Du JY Lahdenranta J Overland R Yarar D Paragas V et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors. Sci Signal (2013) 6(288):ra68.10.1126/scisignal.200400823943608
116. Denlinger CS Sym S Bendell J Alsina M Watkins D Chao Y et al. Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally advanced therapy. J Clin Oncol (2014) 32(5s):abstrTS4148.
117. Britten CD. Targeting ErbB receptor signaling: a pan-ErbB approach to cancer. Mol Cancer Ther (2004) 3(10):1335–42.
118. Dassonville O Bozec A Fischel JL Milano G. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors: similarities and differences. Crit Rev Oncol Hematol (2007) 62(1):53–61.10.1016/j.critrevonc.2006.12.00817324578
119. Yang JL Hannan MT Russell PJ Crowe PJ. Expression of HER1/EGFR protein in human soft tissue sarcomas. Eur J Surg Oncol (2006) 32(4):466–8.10.1016/j.ejso.2006.01.01216524687
120. Wang L Zhang Q Zhang J Sun S Guo H Jia Z et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer (2011) 11:248.10.1186/1471-2407-11-24821676217
121. Albritton KH Rankin C Coffin CM Ratner N Budd GT Schuetze SM et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol (2006) 24(18S):9518.
122. Ha HT Griffith KA Zalupski MM Schuetze SM Thomas DG Lucas DR et al. Phase II trial of cetuximab in patients with metastatic or locally advanced soft tissue or bone sarcoma. Am J Clin Oncol (2013) 36(1):77–82.10.1097/COC.0b013e31823a497022237145
123. Ebb D Meyers P Grier H Bernstein M Gorlick R Lipshultz SE et al. Phase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology group. J Clin Oncol (2012) 30(20):2545–51.10.1200/JCO.2011.37.454622665540